Latest news from the Centre for Drug DevelopmentLatest news from the Centre for Drug Development
Discover the latest news, features and press releases from the Centre for Drug Development and our partners, including drug discovery, licensing, start-up and investment updates.
If you're looking for past updates, browse our news archive for previous articles and inspiring achievements.
Our latest news
CDD and KisoJi partner to advance first naked TROP2 antibody into the clinic
Cancer Research UK and KisoJi Biotechnology have signed a landmark agreement to bring Kisoji's lead asset into a first in human clinical trial. The trial will treat people with TROP2 expressing tumours which include colorectal, head & neck, ovarian, breast and bladder cancers.
Results of our trial of Bicycle Therapeutics' first in class Bicycle® Toxin Conjugate
See the results of our clinical trial of BT1718 in people with squamous non-small cell lung cancer and other MT1-MMP expressing cancers. The trial was led by Professor Udai Banerji at the Institute of Cancer Research.
Our trial of Nxera's cancer immunotherapy at ESMO
Our trial of Nxera's novel EP4 antagonist HTL0039732 led by Dr Bristi Basu at the Cambridge Experimental Cancer Medicine Centre(link is external) was presented at the 2024 European Society for Medical Oncology Congress in Barcelona.
Making a real difference in cancer
Lars Erwig, our Director, talks to The Medicine Maker about about developing treatments for rare cancers and the need for pharma companies to increase collaboration with non-profits to deliver the best outcomes for patients.
First patient dosed in CDD Phase II trial of new pancreatic drug ginisortamab
The first patient has been treated in our trial of UCB's antibody ginisortamab, part of our collaboration with UCB. Ginisortamab will be given with standard chemotherapy to people with advanced pancreatic cancer.
Beyond Borders: going global with clinical trials
Lars Erwig, our Director, talks about the need for global collaboration in clinical trials and international partnerships to pool expertise, resources and patients.
CDD and the Norwegian Cancer Society partner to bring more novel treatments into the clinic
Announcing a new multi-project strategic partnership to maximise our unique drug development capabilities to benefit people affected by cancer.
First patient dosed in CDD Phase I trial of Aleta Biotherapeutics' CAR T cell engager
Our trial of first in class drug ALETA001 has treated the first patient. The trial is treating people with B-cell lymphoma whose disease has progressed after receiving CD19 CAR T cell therapy.
Cancer Research UK and Stitch strengthen their partnership, collaborating on two new studies
We're expanding the scope of our pilot study with two further studies launching in spring 2024, providing more trial participants with the enhanced support offered by the Stitch platform.
Director of our Formulation Unit awarded OBE
Cancer Research UK celebrates New Year Honours 2024 with several of its dedicated researchers and supporters recognised for their contributions, including Professor Gavin Halbert, Director of our Formulation Unit.
Delivering the next generation of medicines
We have a strong history of advancing cancer treatments and an active development portfolio of over 20 agents.
Partnering with us
We partner with academics, pharmaceutical, and biotech companies worldwide to develop novel cancer treatments.
Involving patients in our work
From clinical trial planning to patient centred trial management apps, we’re consulting, collaborating and partnering with people affected by cancer.